AU2003258957A1 - Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity - Google Patents

Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Info

Publication number
AU2003258957A1
AU2003258957A1 AU2003258957A AU2003258957A AU2003258957A1 AU 2003258957 A1 AU2003258957 A1 AU 2003258957A1 AU 2003258957 A AU2003258957 A AU 2003258957A AU 2003258957 A AU2003258957 A AU 2003258957A AU 2003258957 A1 AU2003258957 A1 AU 2003258957A1
Authority
AU
Australia
Prior art keywords
spirosubstituted
piperidines
obesity
treatment
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003258957A
Other languages
English (en)
Inventor
Duane A. Burnett
Martin S. Domalski
Thavalakulam K. Sasikumar
Wen-Lian Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2003258957A1 publication Critical patent/AU2003258957A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003258957A 2002-06-27 2003-06-26 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity Abandoned AU2003258957A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39181302P 2002-06-27 2002-06-27
US60/391,813 2002-06-27
PCT/US2003/020088 WO2004002987A1 (en) 2002-06-27 2003-06-26 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Publications (1)

Publication Number Publication Date
AU2003258957A1 true AU2003258957A1 (en) 2004-01-19

Family

ID=30000757

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003258957A Abandoned AU2003258957A1 (en) 2002-06-27 2003-06-26 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Country Status (14)

Country Link
US (1) US7109207B2 (enExample)
EP (1) EP1532147B1 (enExample)
JP (1) JP4522853B2 (enExample)
CN (1) CN100374440C (enExample)
AR (1) AR040344A1 (enExample)
AT (1) ATE334983T1 (enExample)
AU (1) AU2003258957A1 (enExample)
CA (1) CA2490531C (enExample)
DE (1) DE60307289T2 (enExample)
ES (1) ES2266861T3 (enExample)
MX (1) MXPA05000185A (enExample)
PE (1) PE20040749A1 (enExample)
TW (1) TW200401777A (enExample)
WO (1) WO2004002987A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
US7727998B2 (en) 2003-02-10 2010-06-01 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
JP4570165B2 (ja) * 2003-02-28 2010-10-27 シェーリング コーポレイション 肥満および関連障害の処置のための選択的ｍｃｈレセプターアンタゴニストとしてのビアリールテトラヒドロイソキノリンピペリジン
BRPI0509307A (pt) 2004-03-29 2007-09-04 Pfizer compostos de alfa aril ou heteroaril metil beta piperidino propanamida como antagonistas do receptor orl1
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
JPWO2006104136A1 (ja) * 2005-03-29 2008-09-11 萬有製薬株式会社 非アルコール性脂肪性肝疾患の治療剤、及び非アルコール性脂肪性肝疾患の治療又は予防のための薬剤の候補化合物のスクリーニング方法
US8247442B2 (en) * 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US20090247560A1 (en) * 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US9963739B2 (en) 2010-05-21 2018-05-08 Hewlett-Packard Development Company, L.P. Polymerase chain reaction systems
WO2011146069A1 (en) 2010-05-21 2011-11-24 Hewlett-Packard Development Company, L.P. Fluid ejection device including recirculation system
JP2017535545A (ja) * 2014-11-21 2017-11-30 ラボラトリオス・デル・デエレ・エステベ・エセ・ア 疼痛に対する多様な活性を有するスピロ−イソキノリン−１，４’−ピペリジン化合物
CN107312056B (zh) * 2017-08-24 2019-10-25 广西师范学院 2-(3’-羟基-17’-孕甾烷基)-5-氟苯并咪唑的合成方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908830A (en) 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
CA2381111A1 (en) 1999-08-26 2001-03-01 Leah M. Giupponi Npy antagonists: spiroisoquinolinone derivatives
JP2003527444A (ja) 2000-03-23 2003-09-16 メルク エンド カムパニー インコーポレーテッド メラノコルチン受容体アゴニストとして作用するスピロピペリジン誘導体
AU783403B2 (en) * 2000-07-05 2005-10-20 H. Lundbeck A/S Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof

Also Published As

Publication number Publication date
CA2490531C (en) 2011-03-22
ES2266861T3 (es) 2007-03-01
AR040344A1 (es) 2005-03-30
EP1532147A1 (en) 2005-05-25
HK1071567A1 (en) 2005-07-22
US20040024002A1 (en) 2004-02-05
EP1532147B1 (en) 2006-08-02
PE20040749A1 (es) 2004-10-23
DE60307289D1 (de) 2006-09-14
CN100374440C (zh) 2008-03-12
WO2004002987A1 (en) 2004-01-08
US7109207B2 (en) 2006-09-19
MXPA05000185A (es) 2005-04-08
JP4522853B2 (ja) 2010-08-11
CA2490531A1 (en) 2004-01-08
TW200401777A (en) 2004-02-01
ATE334983T1 (de) 2006-08-15
DE60307289T2 (de) 2007-10-18
JP2005535641A (ja) 2005-11-24
CN1665812A (zh) 2005-09-07

Similar Documents

Publication Publication Date Title
AU2003243497A1 (en) Antagonists of melanin concentrating hormone receptor
EP1653960A4 (en) MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST
AU2003258957A1 (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
AU7109000A (en) Dibenzopyrans as glucocorticoid receptor antagonists for treatment of diabetes
HUE039348T2 (hu) A2A receptor antagonisták mozgási rendellenességek kezelésében történõ alkalmazásra
AU2003287880A1 (en) Cyclic quinoline compounds for use in mch receptor related disorders
HUP0202253A3 (en) Selective iglur5 receptor antagonists for the treatment of migraine
AU2003255501A1 (en) Cxcr4 receptor antagonists
AU2003290059A1 (en) Use of cd137 antagonists for the treatment of tumors
TW524111U (en) Multifunctional adjustment device for wheelchair
IL166344A0 (en) Device for tectile stimulation
AU2003267088A1 (en) Chemokine receptor antagonists as therapeutic agents
AU2003218760A1 (en) Device for stimulating at least one person
AU2003300904A1 (en) Antagonists for human prolactin
AU2003268117A1 (en) Histamine h3 receptor antagonists, preparaton and therapeutic uses
AU2003256793A1 (en) Substituted azepines as histamine h3 receptor antagonists, preparation and therapeutic uses
IL174370A0 (en) Melanin concentrating hormone antagonists
AU2003280745A8 (en) Ring-opened polynorbornenes
AU2003264297A1 (en) Use of vanilloid receptor antagonists for the treatment of pain
HK1087917A (en) Aminobenzimidazoles as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
AU2003274320A1 (en) Electrodes for therapeutic apparatus
HK1087407A (en) 2-substituted benzimidazole piperidines analogs as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
AU2003245995A1 (en) Use of gaba-c receptor antagonists for the treatment of myopia
HK1104033A (en) Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
AU2003297124A1 (en) F11 receptor(f11r) antagonists as therapeutic agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase